GlassScriptPhysician profile
Asif Jawaid
NPI 1922483841
$15,269.01
in general payments reported to CMS, 2019-2025
40 companies · $1,360 in 2025
The $1,360 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,532 · 2020: $1,286 · 2021: $2,808 · 2022: $1,309 · 2023: $2,809 · 2024: $3,166 · 2025: $1,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,275 · Travel and Lodging: $1,044 · Consulting Fee: $15.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,275.30 |
| Travel and Lodging | $1,044.03 |
| Consulting Fee | $15.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,657.49 | 2021-2025 | Resolute Onyx, Symplicity G3, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $1,680.06 | 2019-2025 | Tacticath Ablation Catheter, Sensor Enabled, Cardiomems, Ensite |
| Philips North America LLC | $1,405.84 | 2019-2025 | (7881) US Und, (Bh4) Igt Devices Undivided, (Bq9) Coronary Ivus |
| Penumbra, INC. | $1,123.28 | 2021-2022 | |
| Cook Medical LLC | $1,114.19 | 2019-2024 | Zilver Ptx, Rosen |
| Boston Scientific Corporation | $796.87 | 2019-2025 | Watchman Flx, Bodyguardian |
| Abiomed | $783.31 | 2021-2025 | Impella |
| Shockwave Medical, INC | $717.42 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Cardiovascular Systems INC. | $706.05 | 2019-2022 | |
| Terumo Medical Corporation | $488.60 | 2019-2024 | Glidesheath Slender, Metacross Otw, Heartrail |
| Heartflow, INC. | $396.12 | 2023-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $347.13 | 2019-2022 | |
| Edwards Lifesciences Corporation | $331.49 | 2023-2024 | |
| Astellas Pharma US INC | $316.79 | 2020-2021 | |
| Medtronic Vascular, INC. | $305.22 | 2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $261.45 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $238.97 | 2019-2024 | Farxiga |
| Pfizer INC. | $209.00 | 2019-2024 | |
| Endologix LLC | $175.91 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $171.20 | 2022-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.21 | 2023-2024 | Jardiance |
| Atricure, INC. | $132.63 | 2021 | |
| Irhythm Technologies, INC. | $129.40 | 2022-2023 | Zio Xt Patch |
| Amarin Pharma, INC. | $79.86 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $74.78 | 2023-2024 | Optimizer, Optimizer |
| Novartis Pharmaceuticals Corporation | $73.40 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $72.51 | 2019-2024 | Lifevest |
| Insulet Corporation | $50.84 | 2020 | |
| Cvrx, INC. | $43.63 | 2023-2024 | Barostim Neo System |
| Amgen INC. | $33.07 | 2025 | Repatha |
| Kiniksa Pharmaceuticals International, Plc | $24.80 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Scpharmaceuticals INC. | $19.63 | 2024 | |
| Ekos Corporation | $18.97 | 2019 | |
| Novo Nordisk INC | $18.79 | 2023 | Ozempic |
| Kiniksa Pharmaceuticals, LTD. | $18.53 | 2021 | |
| Asahi Intecc USA, INC. | $18.46 | 2024 | Peripheral Vascular |
| Ge Healthcare | $18.29 | 2021 | |
| Baxter Healthcare | $15.00 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Cashflow Solutions, LLC | $14.82 | 2025 | Pcd-51 731a (US) - White, Pcd-52 737a (US) White, Lympha Press Optimal Plus(US) Bt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asif Jawaid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.